About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

NCT01207011·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Sumitomo Pharma Co., Ltd.

Age

20–74

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Histological or cytological diagnosis of non-small cell lung cancer (NSCLC)
1 or 2 prior chemotherapy regimen including 1 platinum-based chemotherapy
20 or older but younger than 75 years of age

You may not be if

Symptomatic brain metastasis
Interstitial pneumonia or pulmonary fibrosis
Abnormal cardiac function or myocardial infraction within 6 months before study enrollment
Active infection

The record

StatusCompleted

PhasePhase 3

Taking part202

StartedOct 2010

UpdatedApr 12, 2022

Conditions

Where1

32 Sites
Multiple Locations, Japan